DrugDashboards

Fondaparinux Sodium

Fondaparinux Sodium · FONDAPARINUX SODIUM 7.5 mg/.6mL · Injection · Subcutaneous · Sandoz Inc.

NDC 00781-3465-95 · 10 SYRINGE in 1 CARTON / .6 mL in 1 SYRINGE · ANDA · View full market →

The short version

Just 2 companies supply this market — thin enough that a single exit would be felt immediately. The price is up 9% over the past year, to $42.71 per mL. Put together: worth watching — several of the pressures that precede supply trouble are present at once. Historically, drugs in this position went on to a new shortage within 90 days about 0.6% of the time — roughly 4× the typical drug (0.1%).

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$42.71per MLinvoice-surveyed acquisition cost · Aug 19, 2026
  • Medicare Part B pays (ASP+6%)$0.9250per billing unit (0.5 MG)HCPCS J1652 · Jul 1, 2026
  • Part D plans paid (avg)$67.45per dosage unitgross, before rebates — matched by drug name · 2024
  • Medicaid generic ceiling (FUL)$42.71per MLweighted avg manufacturer price $16.5890 · Aug 1, 2026100% of what pharmacies pay — higher than 10% of drugs with this benchmark

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

$0$25.00$50.00$75.00Feb 2021Sep 2026$42.71
34 price points · per ML · dashed = manufacturer avg (WAMP)Source: CMS NADAC

Estimated fill cost

WAC per package, as filed
$553.00
Reported to Texas DSHS · 2026 annual filing · Sandoz

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicare Part B (ASP)

Payment limit per 0.5 MG
$0.925
HCPCS J1652 · Jul 1, 2026 quarter · typically ASP + 6%

Medicaid spend (2022)

$13,393
11 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

40● Elevated risk

The score is counting real pressure here. One of these alone is routine; it’s the combination that makes this market worth watching.

  • 2 active manufacturers+20
  • sterile injectable+10
  • manufacturer plans to discontinue+10

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.6%chance of a new FDA shortage posting for fondaparinux sodium (injectable) in the next 90 days

sterile injectable · OAI inspection at a producing facility (24 months) · sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is 4× that.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 2 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill · avg $1,121.26 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA206812
TE code
—
Approval date
May 15, 2018
Patents / exclusivity
None on file

Shortage history

  • Planned discontinuation — Fondaparinux Sodium, Injection, 10 mg/.8 mL (NDC 0781-3476-95)Sep 29, 2025
  • Planned discontinuation — Fondaparinux Sodium, Injection, 2.5 mg/.5 mL (NDC 0781-3443-95)Sep 29, 2025
  • Planned discontinuation — Fondaparinux Sodium, Injection, 5 mg/.4 mL (NDC 0781-3454-95)Sep 29, 2025
  • Planned discontinuation — Fondaparinux Sodium, Injection, 7.5 mg/.6 mL (NDC 0781-3465-95)Sep 29, 2025

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Fondaparinux Sodium (Injection)

LabelerStrengthFirst seenLast seen
Dr. Reddy's Laboratories LimitedFONDAPARINUX SODIUM 5 mg/.4mLJul 15, 2026Sep 2, 2026
Dr. Reddy's Laboratories LimitedFONDAPARINUX SODIUM 10 mg/.8mLJul 15, 2026Sep 2, 2026
Dr. Reddy's Laboratories LimitedFONDAPARINUX SODIUM 7.5 mg/.6mLJul 15, 2026Sep 2, 2026
Dr. Reddy's Laboratories LimitedFONDAPARINUX SODIUM 2.5 mg/.5mLJul 15, 2026Sep 2, 2026
Sandoz Inc.FONDAPARINUX SODIUM 7.5 mg/.6mLJul 15, 2026Sep 2, 2026
Sandoz Inc.FONDAPARINUX SODIUM 2.5 mg/.5mLJul 15, 2026Sep 2, 2026
Sandoz Inc.FONDAPARINUX SODIUM 5 mg/.4mLJul 15, 2026Sep 2, 2026
Sandoz Inc.FONDAPARINUX SODIUM 10 mg/.8mLJul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Fondaparinux Sodium — NDC 00781-3465-95," retrieved September 3, 2026, https://drugdashboards.com/drug/00781346595.

Free to cite with attribution — see how the data is put together.